GeoffreyWChanMD

PubMed

• 2 citations
  Evaluation of the Relationship of Glasdegib Exposure and Safety End Points in Patients With Refractory Solid Tumors and Hematologic Malignancies.
  Ana Ruiz-Garcia, Naveed Shaik, Swan Lin, Catriona Jamieson, Michael Heuser, Geoffrey Chan> ;Journal of Clinical Pharmacology. 2021 Mar 1
• 4 citations
  Evaluation of the impact of renal impairment on the pharmacokinetics of glasdegib in otherwise healthy volunteers.
  Naveed Shaik, Robert R. LaBadie, Brian Hee, Geoffrey Chan> ;Cancer Chemotherapy and Pharmacology. 2021 Jan 3
• 5 citations
  An evaluation of overall survival in patients with newly diagnosed acute myeloid leukemia and the relationship with glasdegib treatment and exposure
  Swan Lin, Naveed Shaik, Geoffrey Chan, Jorge E. Cortes, Ana Ruiz-Garcia> ;Cancer Chemotherapy and Pharmacology. 2020 Sep 3
• 341 citations
  Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome
  Jorge E. Cortes, Florian H. Heidel, Andrzej Hellmann, Walter Fiedler, B. Douglas Smith, Tadeusz Robak, Pau Montesinos, Daniel A. Pollyea, Pierre Desjardins, Oliver G. ...> ;Leukemia. 2019 Feb 1
• 85 citations
  Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
  Jorge E. Cortes, B. Douglas Smith, Eunice S. Wang, Akil Merchant, Vivian G. Oehler, Martha Arellano, Daniel J. DeAngelo, Daniel A. Pollyea, Mikkael A. Sekeres, Tadeusz...> ;American Journal of Hematology. 2018 Nov 1
• 133 citations
  Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial
  John D. Grainger, Franco Locatelli, Thirachit Chotsampancharoen, Elena K. Donyush, Bunchoo Pongtanakul, Patcharee Komvilaisak, Darintr Sosothikul, Guillermo Drelichman...> ;Lancet. 2015 Oct 24
• 54 citations
  Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia:...
  Uwe Platzbecker, Raymond S.M. Wong, Amit Verma, Camille N. Abboud, Sergio Araujo, Tzeon Jye Chiou, John Feigert, Shih-Peng Yeh, Katharina Götze, Gorin Nc, Peter L. Gre...> ;The Lancet. Haematology. 2015 Oct 1
• 113 citations
  Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study
  James B. Bussel, Purificación García de Miguel, Jenny M. Despotovic, John D. Grainger, Julián Sevilla, Victor S. Blanchette, Lakshmanan Krishnamurti, Philip Connor, Mi...> ;The Lancet. Haematology. 2015 Aug 1
• 4 citations
  An open-label, single-arm, phase 1 study to assess biomarker effects, efficacy and safety of ofatumumab in patients with refractory chronic lymphocytic leukemia
  William N. Patton, Robert Lindeman, Andrew C Butler, Thomas J. Kipps, Roxanne C. Jewell, Kevin H. Laubscher, Yan Yan Zhou, Eric Lewis, Donna Sedoti, Philip Witman, Lei...> ;Leukemia & Lymphoma. 2015 Feb 26
• 2 citations
  Assessment of the effect of ofatumumab on cardiac repolarization.
  Roxanne C. Jewell, Kevin H. Laubscher, Eric Lewis, Lei Fang, Zarina Gafoor, Jodi L Carey, Astrid McKeown, Sarah West, Oliver Wright, Donna Sedoti, Iestyn Dixon, Charle...> ;Journal of Clinical Pharmacology. 2015 Jan 1
• 123 citations
  Ofatumumab is active in patients with fludarabine-refractory CLL irrespective of prior rituximab: results from the phase 2 international study.
  William G. Wierda, Swaminathan Padmanabhan, Geoffrey W. Chan, Ira Gupta, Steen Lisby, Anders Österborg> ;Blood. 2011 Nov 10
• 89 citations
  Chemoimmunotherapy with O-FC in previously untreated patients with chronic lymphocytic leukemia.
  William G. Wierda, Thomas J. Kipps, Jan Dürig, Laimonas Griskevicius, Stephan Stilgenbauer, Jiří Mayer, Lukas Smolej, Georg Hess, Rasa Griniute, Francisco J. Hernandez...> ;Blood. 2011 Jun 16
• 71 citations
  Blood stream infection (BSI) and acute GVHD after hematopoietic SCT (HSCT) are associated
  Debra D. Poutsiaka, David Munson, Lori Lyn Price, Geoffrey W. Chan, David R. Snydman> ;Bone Marrow Transplantation. 2011 Feb 1
• 458 citations
  Ofatumumab As Single-Agent CD20 Immunotherapy in Fludarabine-Refractory Chronic Lymphocytic Leukemia
  William G. Wierda, Thomas J. Kipps, Jiří Mayer, Stephan Stilgenbauer, Cathy D. Williams, Andrzej Hellmann, Tadeusz Robak, Richard R. Furman, Peter Hillmen, Marek Trnen...> ;Journal of Clinical Oncology. 2010 Apr 1
• Clinical improvement with a novel CD20 mAb, ofatumumab, in fludarabine-refractory chronic lymphocytic leukemia (CLL) also refractory to alemtuzumab or with bulky lymph...
  Kipps TJ, Österborg A, Mayer J, Stilgenbauer S, Hellmann A, Williams CD, Furman R, Chan G, Russell C, Wierda WG> ;J. Clin. Oncol.. 2009-05-20
• Activity of ofatumumab, a novel CD20 mAb, and prior rituximab exposure in patients with fludarabine- and alemtuzumab-refractory or bulky fludarabine-refractory chronic...
  Wierda WG, Kipps T, Mayer J, Stilgenbauer S, Robak T, Williams CD, Furman R, Chan G, Russell C, Österborg A> ;J. Clin. Oncol.. 2009-05-20
• 40 citations
  Complete remission in a patient with acute myelogenous leukemia treated with erlotinib for non–small-cell lung cancer
  Geoffrey W. Chan, Monika Pilichowska> ;Blood. 2007 Aug 1
• 151 citations
  Blood stream infection after hematopoietic stem cell transplantation is associated with increased mortality.
  Debra D. Poutsiaka, Lori Lyn Price, A Ucuzian, Geoffrey W. Chan, Kenneth B. Miller, David R. Snydman> ;Bone Marrow Transplantation. 2007 Apr 30
• 147 citations
  Prospective study of extracorporeal photopheresis in steroid-refractory or steroid-resistant extensive chronic graft-versus-host disease: analysis of response and surv...
  Francine M. Foss, Gina DiVenuti, Kevin M. Chin, Kellie Sprague, H Grodman, Andreas K. Klein, Geoffrey W. Chan, K Stiffler, Kenneth B. Miller> ;Bone Marrow Transplantation. 2005 Jun 1
• 2 citations
  GM-CSF and low-dose cytosine arabinoside in high-risk, elderly patients with AML or MDS.
  Eric S. Winer, Kenneth B. Miller, Geoffrey W. Chan> ;Oncology. 2005 Apr 1
• Priming GM-CSF and low dose cytarabine (LODAC) in the treatment of high risk and elderly acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) patients.
  Winer ES, Miller KB, Chan GW> ;J. Clin. Oncol.. 2004-07-15
• 23 citations
  Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease.
  Geoffrey W. Chan, Francine M. Foss, Andreas K. Klein, Kellie Sprague, Kenneth B. Miller> ;Biology of Blood and Marrow Transplantation. 2003 Dec 1
• 63 citations
  Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease.
  Geoffrey W. Chan, Gullu Gorgun, Kenneth B. Miller, Francine M. Foss> ;Biology of Blood and Marrow Transplantation. 2003 Mar 1
• 36 citations
  Danazol for the treatment of thrombocytopenia in patients with myelodysplastic syndrome
  Geoffrey W. Chan, Gina DiVenuti, Kenneth B. Miller> ;American Journal of Hematology. 2002 Nov 1
• Join now to see all

Abstracts/Posters

• Clinical Benefit of Glasdegib in Combination with Azacitidine or Low-Dose Cytarabine in Patients with Acute Myeloid LeukemiaClinically Relevant Abstract
  Geoffrey Chan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase 1b Study of Glasdegib in Combination with Azacitidine in Patients with Untreated Higher-Risk Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Mye...
  Geoffrey Chan, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019